The Osteosarcoma market presents opportunities in developing novel therapies, with over 25 companies working on 32+ drugs in the pipeline. There is strong focus on Phase III products like HS-20093, and innovative approaches like TGF-β1 inhibitors and CAR-T therapies, indicating significant R&D prospects and unmet needs in this space. The Osteosarcoma market presents opportunities in developing novel therapies, with over 25 companies working on 32+ drugs in the pipeline. There is strong focus on